A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
The aim of the trial is to assess the benefit of adding high precision radiation therapy to chemotherapy and surgery for the treatment of pancreatic cancer.
Primary Sponsor
Australasian Gastro-Intestinal Trials Group (AGITG)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG) and NHMRC CTC
Accrual Target
120
Expected Date of Accrual
31 December 2024
Trial Chairperson
Dr Andrew Oar, Gold Coast University Hospital
Trial Contact
MASTERPLAN.study@sydney.edu.au
Clinical Trial Registration
Related Post
21 October, 2026
Jess’s deeply personal reason for joining TROG’s Km’s for Cancer Research challenge
LATEST NEWS: 21 October 2026 For Jess Synge, taking
14 October, 2026
New FET-PET imaging approach helps target radiotherapy for glioblastoma, FIG trial – TROG 18.06 finds
LATEST NEWS: 14 October 2026 Adding a FET-PET brain